Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Advances in Radiation Oncology|August 12, 2017
Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinomaMostafa Mohamed, Alan W Katz, Mohamedtaki A Tejani, et al.
Cancer Medicine|May 2, 2022
A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyondMarcus S Noel, Semmie Kim, Marion L Hartley, et al.
International Journal of Radiation Oncology, Biology, Physics|September 17, 2023
Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC)Benjamin A Weinberg, Hongkun Wang, Marcus S Noel, et al.
Journal of Gastrointestinal Cancer|February 12, 2024
Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locally Advanced Pancreatic CancerNicole Libbey, Lindsey Gallagher, Jonathan Cantalino, et al.
Cancers|March 29, 2023
Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways and COP1 in MetastasisJerry Xiao, Utsav Sharma, Abolfazl Arab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Cell Reports. Medicine|May 7, 2026
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial resultsDavid A Braun, Marcus S Noel, Ryan H Moy, et al.
Cancer Research Communications|February 5, 2025
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction CancersAndrew H Ko, Joseph Chao, Marcus S Noel, et al.
Eclinicalmedicine|March 27, 2023
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trialTanios Bekaii-Saab, Takuji Okusaka, David Goldstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced MalignanciesGerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Pageof 3